Welcome to our dedicated page for Boston Scien Cp news (Ticker: BSX), a resource for investors and traders seeking the latest updates and insights on Boston Scien Cp stock.
Boston Scientific Corporation (NYSE: BSX) is a global medical technology company whose news flow reflects activity across cardiovascular, neuromodulation, urology, endoscopy and other therapeutic areas. Company announcements frequently describe new agreements to acquire medical technology firms, clinical and regulatory milestones for key product platforms, and detailed quarterly financial results.
Recent news includes a definitive agreement to acquire Penumbra, Inc. in a cash and stock transaction. Penumbra has developed mechanical thrombectomy and neurovascular devices to treat conditions such as pulmonary embolism, stroke, deep vein thrombosis, acute limb ischemia, heart attack and aneurysms, with products like the Lightning Bolt and Lightning Flash computer assisted vacuum thrombectomy systems and peripheral embolization technologies. Boston Scientific has also announced an agreement to acquire Valencia Technologies Corporation, adding the eCoin implantable tibial nerve stimulation system for urge urinary incontinence, and an agreement to acquire Nalu Medical, Inc., developer of the Nalu Neurostimulation System for peripheral nerve stimulation in chronic pain.
In addition to acquisition news, Boston Scientific regularly issues earnings releases detailing net sales by business and region, growth rates on reported, operational and organic bases, and commentary on segment performance in MedSurg and Cardiovascular. These releases often highlight regulatory approvals, such as expanded labeling for the FARAPULSE Pulsed Field Ablation System or CE marks for devices like the WATCHMAN FLX Pro Left Atrial Appendage Closure Device, as well as clinical study results, including long-term data from deep brain stimulation trials.
Investors and observers following BSX news can also expect updates on investor conferences, investor day events, and governance matters disclosed through press releases and Form 8-K filings. This page aggregates such coverage, offering a centralized view of Boston Scientific’s strategic transactions, product developments, financial updates and corporate announcements over time.
Boston Scientific (NYSE: BSX) agreed to acquire Penumbra (NYSE: PEN) in a cash-and-stock deal valuing Penumbra at $374 per share, implying an enterprise value of about $14.5 billion. Consideration is ~73% cash and ~27% stock, with a 3.8721 BSX share election per PEN share. Penumbra expects 2025 reported revenue of ~$1.4 billion (growth ~17.3%–17.5%) and Q4 growth ~21.4%–22.0%. Boston Scientific plans to finance roughly $11 billion of the cash portion with cash on hand and new debt. The deal is expected to close in 2026, subject to approvals, and to be mildly dilutive to adjusted EPS by $0.06–0.08 in year one, turning neutral/acc-retive thereafter.
Boston Scientific (NYSE: BSX) agreed to acquire Valencia Technologies to add the eCoin implantable tibial nerve stimulation (ITNS) system for urge urinary incontinence (UUI). The eCoin device is FDA-approved (2022) and showed a 68% responder rate (>=50% UUI reduction) in the pivotal trial. Boston Scientific said the deal is expected to close in H1 2026, will expand its urology and pelvic health portfolio, and aims to broaden minimally invasive treatment options for overactive bladder. The company expects an immaterial impact on adjusted EPS in 2026 but greater GAAP dilution from acquisition-related charges and amortization; transaction terms were not disclosed.
Boston Scientific (NYSE: BSX) will participate in the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 with a 40-minute Q&A starting at approximately 9:00 a.m. PT / 12:00 p.m. ET. Presenters include Mike Mahoney (chairman & CEO), Jon Monson (EVP & CFO) and Ken Stein, M.D. (SVP & global chief medical officer).
The company will also host a webcast conference call to discuss fourth quarter and full year results for the period ended December 31, 2025 on February 4, 2026 at 8:00 a.m. ET, preceded by a news release. Live webcasts and replays will be available at https://investors.bostonscientific.com, with replays posted about one hour after each event.
CathVision (BSX) announced two milestones on Dec 10, 2025: the appointment of Eric Thepaut as independent Chairman of the Board and the commercial release of ECGenius System Version 3.5.
Thepaut joins after retirement from Boston Scientific, bringing commercial and integration experience. CathVision said ECGenius and Cardialytics were FDA-cleared in 2023 and ECGenius received CE mark in 2025. Version 3.5 adds user interface flexibility, DICOM archiving, hospital worklist integration, hardware refinements to reduce post-pacing artifacts, and streamlined 12-lead ECG capture.
Boston Scientific (NYSE: BSX) will present at two investor conferences in late 2025. On November 18, 2025 at ~8:00 a.m. ET Kenneth Stein, M.D., and Lauren Tengler will join a 30-minute Q&A at Wolfe Research's 7th Annual Healthcare Conference. On December 2, 2025 at ~9:00 a.m. ET Joe Fitzgerald, Janar Sathananthan, M.D., and Lauren Tengler will join a 40-minute Q&A at Citi's 2025 Global Healthcare Conference. Live webcasts and replays for both events will be accessible at the company investor site, with replays available about one hour after each event ends.
Boston Scientific (NYSE: BSX) reported Q3 2025 net sales of $5.065B, up 20.3% reported, 19.4% operational and 15.3% organic versus prior year. GAAP EPS was $0.51 and adjusted EPS was $0.75, above guidance ranges. By segment, Cardiovascular sales were $3.343B (+22.4%) and MedSurg sales were $1.722B (+16.4%). Regional highlights included the U.S. up 27.0% and APAC up 17.1%; EMEA was roughly flat. Company updated full-year 2025 guidance: ~20% reported net sales growth, GAAP EPS $1.97–$2.01, adjusted EPS $3.02–$3.04. Announced completed Elutia asset acquisition and agreement to acquire Nalu Medical.
Boston Scientific (NYSE: BSX) agreed to acquire Nalu Medical for an upfront cash payment of approximately $533 million for remaining equity ($600 million on a 100% basis before Boston Scientific ownership). The deal expands Boston Scientific's neuromodulation portfolio with Nalu's miniaturized, battery-free Nalu Neurostimulation System for peripheral nerve stimulation (PNS), cleared by the FDA 510(k) in 2019.
Clinical data cited: COMFORT 87% >50% pain reduction at 12 months; COMFORT 2 79% of patients with 64% average pain relief at 6 months; real-world data from >2,000 patients with 94% clinically meaningful improvement. Boston Scientific expects close in H1 2026, Nalu sales > $60M in 2025 and >25% YoY growth in 2026; adjusted EPS impact: immaterial 2026, slightly accretive 2027, while GAAP EPS is expected to be dilutive initially.
Boston Scientific (NYSE: BSX) has announced two upcoming investor events. The company will host its 2025 Investor Day on September 30, 2025, at 8:30 a.m. ET in a hybrid format, where management will discuss financial goals and long-term growth strategies.
Additionally, BSX will hold its Q3 2025 earnings conference call on October 22, 2025, at 8:00 a.m. ET. The call will feature Chairman and CEO Mike Mahoney and CFO Jon Monson. Both events will be webcast live and available for replay on the company's investor relations website.
Creative Media and Community Trust (NASDAQ: CMCT) has secured a significant lease agreement with Boston Scientific Corporation (NYSE: BSX) at its Penn Field Campus in Austin, Texas. The approximately 11-year lease covers a 30,821-square-foot building, bringing the property's occupancy to 93%.
The Penn Field Campus, spanning 228,000 square feet across 16 acres in Austin's "SoCo" Business District, is a historic property originally developed in 1918 as a U.S. Army air base. The property has been transformed into a modern office campus while maintaining its historical character, featuring landscaped grounds and diverse tenants from technology, media, and entertainment sectors.
Boston Scientific (NYSE: BSX) reported strong Q2 2025 financial results, with net sales reaching $5.061 billion, representing a 22.8% reported growth and 17.4% organic growth year-over-year. The company achieved GAAP EPS of $0.53 and adjusted EPS of $0.75, both exceeding guidance.
Key segment performance showed robust growth, with Cardiovascular up 26.8% and MedSurg up 15.7% reported. The U.S. market led regional performance with 30.7% growth. Notable developments include FDA approval for expanded FARAPULSE™ PFA System use and strategic acquisitions of Intera Oncology and SoniVie.
The company raised its full-year 2025 guidance to 18-19% reported growth and 14-15% organic growth, with adjusted EPS projected at $2.95-$2.99.
FAQ
What is the current stock price of Boston Scien Cp (BSX)?
What is the market cap of Boston Scien Cp (BSX)?
